Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 10/20 | 0.73 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.73 |
| ▸ | IL6 | P05231 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4125175 | 0.92 | TLR7 (0.69) | TLR7NUDT1IL6 | |
| SCHEMBL4134183 | 0.91 | TLR7 (0.74) | TLR7IL6 | |
| SCHEMBL1146177 | 0.91 | TLR7 (0.85) | TLR7NUDT1IL6 | |
| SCHEMBL4122398 | 0.90 | TLR7 (0.66) | TLR7NUDT1IL6 | |
| SCHEMBL1146487 | 0.89 | TLR7 (0.75) | TLR7NUDT1IL6 | |
| SCHEMBL4133116 | 0.88 | TLR7 (0.66) | TLR7NUDT1IL6 | |
| SCHEMBL1146727 | 0.88 | TLR7 (0.79) | TLR7NUDT1IL6 | |
| SCHEMBL1146403 | 0.87 | TLR7 (0.71) | TLR7NUDT1IL6 | |
| SCHEMBL1146292 | 0.85 | TLR7 (0.75) | TLR7NUDT1IL6 | |
| SCHEMBL29997135 | 0.85 | TLR7 (0.82) | TLR7NUDT1IL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105212-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2009-04-23 | — | — | US | claimed |
| EP-1939201-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | claimed |
| US-20090105212-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20090105212-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20090105212-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1939201-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105212-A1 | NOVEL ADENINE COMPOUND | XDH, ADORA1, NUDT1 | TLR7 396/4885NUDT1 3/4885IL6 3519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.